linkedin Created with Sketch. twitter Created with Sketch. instagram Created with Sketch.
Shape
← Back to portfolio Porfolio / PredictImmune

PredictImmune

Developer of pioneering prognostic tools

Company overview

Founded in May 2017 and based at the Babraham Research Campus in Cambridge, PredictImmune develops pioneering tools for guiding treatment options in immune-mediated inflammatory diseases like Crohn’s and ulcerative colitis (IBD).

Based on ten years of research at Cambridge University, PredictImmune’s test kits help both clinicians and patients to understand, at the point of diagnosis, the likely course of disease and opens the possibility of better treatment choices from the outset.

Website
PredictImmune

Company information

Head office
  • Cambridge
CEO
  • Paul Kinnon
Chair
  • Andrew P Sandham
BGF office
Investment date
  • Jul 2019
Total BGF investment
  • £4 million